Debate Over Cost-Effectiveness of DPYD Testing Before Capecitabine in Metastatic Breast Cancer

A routine genetic test performed before capecitabine treatment could help prevent some of the most serious and avoidable toxic reactions experienced by patients with metastatic breast cancer, according to a new correspondence published in Breast Cancer Research and Treatment. The authors argue that testing the DPYD gene should no longer be viewed only as a promising pharmacogenomic concept, but as a practical clinical strategy whose success will depend on how effectively hospitals integrate genetic results into everyday oncology decisions. Their commentary responds to a 2026 cost-effectiveness analysis by Chiddarwar, Blaes and Kuntz, which examined whether DPYD genotyping before capecitabine administration represents good value in metastatic breast cancer care. The new article supports that conclusion while broadening the discussion beyond financial calculations to include laboratory logistics, ancestry, clinical decision-making and long-term monitoring.

Capecitabine is an oral chemotherapy drug widely used against several cancers, including metastatic breast cancer. After patients take it, the drug is converted inside the body into 5-fluorouracil, or 5-FU, a fluoropyrimidine that interferes with DNA and RNA production in rapidly dividing cells. This mechanism can slow or destroy cancer cells, but it can also injure healthy tissues. Some patients develop severe diarrhea, painful inflammation of the mouth, low blood-cell counts, hand-foot syndrome or other complications that may require hospitalization. In rare cases, fluoropyrimidine toxicity can be fatal. The central problem is that patients can respond very differently to the same dose, and standard clinical assessment cannot reliably identify every person at high risk before treatment begins.

The DPYD gene provides instructions for making dihydropyrimidine dehydrogenase, an enzyme responsible for breaking down most of the active fluoropyrimidine compound in the body. When a patient carries certain harmful DPYD variants, the enzyme may work less effectively or be produced in insufficient quantities. As a result, fluoropyrimidine exposure can rise, allowing toxic levels of the drug or its metabolites to persist for longer than expected. A DPYD genotype test searches for selected variants associated with reduced enzyme activity. If a clinically relevant variant is detected, clinicians may choose a lower starting dose, intensify monitoring or select a different treatment, depending on the patient’s genotype, clinical condition and applicable guidelines. The test does not predict every adverse event, but it can reveal an important inherited risk before the first dose is given.

The correspondence emphasizes that the economic value of this approach is closely linked to its clinical consequences. Genotyping introduces an upfront expense for laboratory testing, interpretation and implementation. However, preventing a single severe toxicity episode can avert emergency treatment, inpatient care, supportive medicines, treatment interruption and loss of productivity for patients and families. Avoiding severe toxicity may also preserve the intended cancer-treatment schedule, an especially important consideration in metastatic disease, where maintaining effective systemic therapy can influence symptoms and disease control. Cost-effectiveness models therefore compare the price of testing with the medical costs and health losses associated with preventable toxicity. The authors argue that these calculations should be interpreted alongside real-world feasibility rather than treated as abstract economic exercises detached from clinical workflows.

One of the most important implementation challenges is the selection of genetic variants included in a test. DPYD variation is not distributed uniformly across global populations, and panels designed around variants most frequently studied in one ancestry group may have reduced sensitivity in another. A test that covers only a narrow set of variants can therefore create a misleading impression of safety, particularly in diverse health systems. The authors call for ancestry-aware variant coverage, while also recognizing that ancestry is an imperfect substitute for individual genetic variation. A globally transferable testing framework should be designed to capture clinically meaningful risk across populations, validated in different regions and interpreted cautiously when a patient carries a rare or poorly characterized variant.

Speed is another decisive factor. Genetic testing is most useful when the result is available before treatment begins, not several weeks after a patient has already received multiple doses. Rapid laboratory pathways could allow oncology teams to order testing at the time capecitabine is considered, with results returned quickly enough to guide the initial prescription. This requires more than a capable laboratory. Hospitals need clear sample-collection procedures, secure reporting systems, trained personnel and agreements about what happens when a result is delayed, inconclusive or identifies a variant of uncertain significance. The correspondence presents turnaround time as a clinical safety issue: a technically accurate test that arrives too late may have little practical value.

Genotype information must also be connected directly to prescribing decisions. A laboratory report alone may not change care if clinicians must search for dosing recommendations manually or interpret complex genetic terminology under time pressure. The authors therefore highlight genotype-linked dose decision support, potentially integrated into electronic prescribing systems. Such tools could connect a patient’s DPYD result with approved clinical guidance, flag a high-risk genotype and prompt consideration of dose adjustment or alternative therapy. This approach is intended to reduce transcription errors and variation between institutions. It would not replace oncologist judgment; rather, it would place relevant genetic information at the point where a treatment decision is made, helping convert a molecular finding into an actionable clinical response.

The authors also advocate for budget-impact assessments tailored to individual health systems. Cost-effectiveness asks whether a strategy provides sufficient health benefit for the resources invested, while budget-impact analysis examines what adopting that strategy would mean for the actual finances of a hospital, insurer or national health service. Testing prices, laboratory capacity, hospitalization costs, drug prices, treatment patterns and reimbursement rules differ substantially between countries. A program that is financially attractive in one setting may require phased implementation in another. Previous research has explored the transferability and budget impact of DPYD testing in metastatic breast cancer across three health systems, reinforcing the idea that local conditions matter. The new correspondence argues that adoption plans should be grounded in these practical financial realities.

Real-world toxicity surveillance would provide the feedback needed to determine whether testing works as intended after implementation. Clinical trials and economic models rely on assumptions, but routine-care data can reveal missed variants, unexpected toxicity patterns, delays in testing or inconsistent adherence to dose recommendations. Monitoring could include rates of severe fluoropyrimidine-related adverse events, hospital admissions, treatment discontinuation, dose modifications and outcomes among patients with different genetic backgrounds. Such data could also help improve test panels and clinical protocols over time. The authors’ proposal is therefore not a one-time screening intervention but a continuously evaluated system in which laboratory results, treatment decisions and patient outcomes inform one another.

The broader message is that pharmacogenomics must be judged not only by whether a genetic association is scientifically valid, but also by whether patients can benefit from it equitably. A test may be clinically useful and cost-effective in theory yet fail to improve outcomes if it is unavailable in rural hospitals, unaffordable to patients or poorly represented in electronic medical records. The correspondence frames DPYD testing as an example of implementation justice in precision oncology. For metastatic breast cancer care, the potential reward is considerable: fewer catastrophic toxic reactions, more informed dosing and a safer path to treatment. Turning that potential into routine practice will require collaboration among oncologists, geneticists, pharmacists, laboratories, health economists, policymakers and patients. The authors conclude that ancestry-aware testing, rapid turnaround, decision support, budget planning and outcome surveillance together could make DPYD-guided capecitabine therapy a more operationally feasible and globally equitable standard of care.